Dr. Gregory L. Simpson, M.D.
Dermatology (Dermatology Physician)
2335 E Kashian Ln Ste 208
Fresno, CA 93701
Who else practices at this address →
Fresno County includes primary care (14% of residents) and mental health (29% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Tennessee, Hsc, College of Medicine (2006)
- Years since graduation
- 20
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 563
Licensed in California since 2010, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Medical school: University of Tennessee, Hsc, College of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Dermatology Physician primary
CA license A112941 (first issued 2010; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Community Regional Medical Center Fresno, CA
Medical groups
- Central California Faculty Medical Group Inc (265 clinicians)
- Family Healthcare Network (93 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 563
- Services billed
- 2,758
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Destruction of precancer skin growth, 2-14 growths | 718 | 177 |
| Established patient office or other outpatient visit, 20-29 minutes | 626 | 437 |
| Destruction of precancer skin growth, 1 growth | 419 | 318 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 137 | 31 |
| Biopsy of related skin growth, first growth | 123 | 111 |
| New patient office or other outpatient visit, 30-44 minutes | 72 | 72 |
| Strapping, unna boot | 71 | 11 |
| Established patient office or other outpatient visit, 30-39 minutes | 55 | 35 |
| Established patient office or other outpatient visit, 10-19 minutes | 49 | 21 |
| Injection of drug or substance under skin or into muscle | 38 | 20 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Triamcinolone Acetonide Other prescribers in Fresno, CA | 182 |
| Dupixent Pen (dupilumab) Other prescribers in Fresno, CA | 136 |
| Ketoconazole Other prescribers in Fresno, CA | 107 |
| Warfarin Sodium Other prescribers in Fresno, CA | 68 |
| Humira(Cf) Pen (adalimumab) Other prescribers in Fresno, CA | 65 |
| Minoxidil Other prescribers in Fresno, CA | 59 |
| Clobetasol Propionate Other prescribers in Fresno, CA | 57 |
| Methotrexate (methotrexate sodium) Other prescribers in Fresno, CA | 54 |
| Fluocinonide Other prescribers in Fresno, CA | 49 |
| Taltz Autoinjector (ixekizumab) | 43 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 4 payments worth $96.10 in total to this clinician.
| Laborie Medical Technologies Corp. | $46.00 |
|---|---|
| Amgen Inc. | $35.11 |
| Arcutis Biotherapeutics, Inc. | $14.99 |
| Food and Beverage | $96.10 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $53,141 in research payments for these studies, mostly to the institutions running them.
- Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE)
Janssen Research & Development, LLC - A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Mod…
Janssen Research & Development, LLC - A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy
AbbVie Inc. · Active, not recruiting · NCT05139602
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.